Refine by
Cancer Diagnostics Articles & Analysis: Older
54 articles found
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty. In the era of precision oncology, it has become increasingly common for patients diagnosed with cancer to undergo tumor sequencing. Identifying the mutations that make up a tumor’s genomic landscape can help guide selection of targeted therapies and inform ...
Alfa Cytology has announced cancer diagnostic biomarker development services to enhance precision in oncology research. ...
The development principle of cancer vaccines usually includes the identification of antigens, vaccine formulation, immune activation, and targeting of cancer cells. ...
CDH1 acts as a tumor suppressor by inhibiting the Wnt/β-catenin pathway, which is often dysregulated in cancer. What is the role of CDH1 in cancer? The loss or dysfunction of CDH1 has been implicated in the development and progression of various types of cancer. ...
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal antibodies, that the era of ADC drug development truly began. Driven by increasingly mature technology, ADC drugs have gone through three iterations (Fig. 1). Although ADCs have gone through three iterations, current ...
Enzymes that are specific to the disease itself are often used to diagnose and monitor cancer, heart disease, and liver disease. For example, prostate-specific antigen (PSA) is an enzyme that is produced by the prostate gland and is used to diagnose and monitor prostate cancer. Elevated levels of PSA in the blood can indicate the presence of ...
ELISA is commonly used to diagnose infectious diseases, autoimmune disorders, and even cancer. Another enzyme-based diagnostic tool is polymerase chain reaction (PCR), which can detect and amplify small amounts of DNA or RNA in a patient's sample. ...
Clarice Reid, a true leader and advocate for those affected by sickle cell disease and BioMark Diagnostics Inc. a diagnostic company focused in developing better cancer care management solutions. ...
Today, in the era of personalized medicine, a comprehensive diagnosis that includes not only the morphological aspects of cancer, but a detailed molecular profile must be produced so the appropriate treatment can be tailored by oncologists and other clinicians. ...
Movember is an annual initiative where men from around the globe grow mustaches to raise awareness for men’s health causes, including mental health and suicide prevention, testicular cancer, and prostate cancer. Through events, fundraising, and using mustaches as a light-hearted starting point for important conversations, the movement supports men in taking charge of their health to live ...
CASE PRESENTATION A 70-year-old female recently diagnosed with metastatic pancreatic cancer presented with acute new onset of lower back pain. The patient was taking chemotherapy, participating in a drug therapy trial, and had received radiation therapy. There was no history of acute trauma to the pelvic or acetabular region. Magnetic resonance imaging revealed bilateral fragility fractures, with ...
As September and Blood Cancer Awareness Month wrap up, we want to reflect on a memorable conversation with Karen Thomas, a woman who received clonoSEQ® testing, and her physician, Dr. ...
The day a person receives a cancer diagnosis is likely one of the worst days of their lives. For some new patients, the typical approach may be to seek care from a specialist at an NCCN-designated cancer center. But for the majority of Americans, it will be a community oncologist who guides them through their cancer journey. That’s why Adaptive recently partnered as a sponsor with ...
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”. PROVIDENCE, R.I. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) ...
The share price has fallen 12% to 220p Cancer diagnostics developer Oncimmune Holdings (LON: ONC) is delaying its 12-month results. ...
A cancer diagnosis is a life-changing event. The diagnosis alone is daunting and then suddenly you are faced with difficult decisions – decisions that may affect your care and quality of life. Cancer is a 24/7 diagnosis, it affects daily life and routines. Symptoms and side effects present themselves on their own schedule, not necessarily when it is convenient for you. Recognizing the ...
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. ...
SubB2M is an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc that is found at elevated levels in multiple human cancers. ...
The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. ...
There is a strong relationship between periodontal disease and oral cancer. In patients with tongue cancer, the periodontal disease preceded the tongue cancer. Although periodontal disease and oral cancers are both located in the mouth, until recently, there was never thought to be a connection between the two. New evidence is coming to light to show that those with periodontal disease increase ...